Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Wu, Chia Ying ^a   Yeh, Yi Chun ^a   Yang, Yu Chih ^a   Chou, Ching ^a   Liu, Ming Tsan ^b   Wu, Ho Sheng ^b   Chan, Jia Tsrong ^c   Hsiao, Pei Wen ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b CENTER FOR DISEASE CONTROL   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL; ANTIGEN PRESENTATION; ARTICLE; BAGG ALBINO MOUSE; CERCOPITHECUS; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; INFLUENZA; MOUSE; ORTHOMYXOVIRUS; TRANSGENE; VERO CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; FEMALE; GENE EXPRESSION REGULATION; GLYCOSYLATION; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; TRANSGENES; VERO CELLS;

EID: 77957021632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009784     Document Type: Article

References (48)

1. Nicholson KG (2009) Influenza and vaccine development: a continued battle. Expert Rev Vaccines 8: 373-374.
2. Pandey A, Singh N, Sambhara S, Mittal SK (2010) Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin 6.
3. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO (2004) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. CD001269 p.
4. Trollfors B (2006) General vaccination of children against influenza? Acta Paediatr 95: 774-777.
5. Johansson BE, Brett IC (2007) Changing perspective on immunization against influenza. Vaccine 25: 3062-3065.
6. Sambhara S, Stephenson I (2009) Moving influenza vaccines forward. Expert Rev Vaccines 8: 375-377.
7. Roy P, Noad R (2008) Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 4: 5-12.
8. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943.
9. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, et al. (2009) Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 4: e4667.
10. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, et al. (2007) Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25: 3871-3878.
11. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3: e1501.
12. Galarza JM, Latham T, Cupo A (2005) Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18: 365-372.
13. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26: 5393-5399.
14. Tao P, Luo M, Zhu D, Qu S, Yang Z, et al. (2009) Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol 22: 273-281.
15. Quan FS, Huang C, Compans RW, Kang SM (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81: 3514-3524.
16. Chen BJ, Leser GP, Morita E, Lamb RA (2007) Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81: 7111-7123.
17. Ali A, Avalos RT, Ponimaskin E, Nayak DP (2000) Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 74: 8709-8719.
18. Enami M, Enami K (1996) Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein. J Virol 70: 6653-6657.
19. Gregoriades A, Frangione B (1981) Insertion of influenza M protein into the viral lipid bilayer and localization of site of insertion. J Virol 40: 323-328.
20. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A (2000) Influenza virus matrix protein is the major driving force in virus budding. J Virol 74: 11538-11547.
21. McCown MF, Pekosz A (2006) Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 80: 8178-8189.
22. Ruigrok RW, Barge A, Durrer P, Brunner J, Ma K, et al. (2000) Membrane interaction of influenza virus M1 protein. Virology 267: 289-298.
23. Johansson BE, Bucher DJ, Pokorny BA, Mikhail A, Kilbourne ED (1989) Identification of PR8 M1 protein in influenza virus high-yield reassortants by M1-specific monoclonal antibodies. Virology 171: 634-636.
24. McMurry JA, Johansson BE, De Groot AS (2008) A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccin 4: 148-157.
25. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, et al. (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38: 1404-1413.
26. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P (2008) Cellular proteins in influenza virus particles. PLoS Pathog 4: e1000085.
27. Ott DE, Coren LV, Kane BP, Busch LK, Johnson DG, et al. (1996) Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 70: 7734-7743.
28. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, et al. (2003) Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 278: 10963-10972.
29. Kirchhausen T (2000) Three ways to make a vesicle. Nat Rev Mol Cell Biol 1: 187-198.
30. Brodsky FM, Chen CY, Knuehl C, Towler MC, Wakeham DE (2001) Biological basket weaving: formation and function of clathrin-coated vesicles. Annu Rev Cell Dev Biol 17: 517-568.
31. Hamby SE, Hirst JD (2008) Prediction of glycosylation sites using random forests. BMC Bioinformatics 9: 500.
32. Schwarzer J, Rapp E, Reichl U (2008) N-glycan analysis by CGE-LIF: profiling influenza A virus hemagglutinin N-glycosylation during vaccine production. Electrophoresis 29: 4203-4214.
33. Robertson JS (1987) Sequence analysis of the haemagglutinin of A/Taiwan/1/ 86, a new variant of human influenza A(H1N1) virus. J Gen Virol 68(Pt 4): 1205-1208.
34. Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, et al. (2003) Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 307: 90-97.
35. Schwarzer J, Rapp E, Hennig R, Genzel Y, Jordan I, et al. (2009) Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine 27: 4325-4336.
36. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, et al. (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 81: 1779-1783.
37. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, et al. (2001) A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183: 1485-1493.
38. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651.
39. Galarza JM, Latham T, Cupo A (2005) Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18: 244-251.
40. Blonder J, Terunuma A, Conrads TP, Chan KC, Yee C, et al. (2004) A proteomic characterization of the plasma membrane of human epidermis by high-throughput mass spectrometry. J Invest Dermatol 123: 691-699.
41. Foster LJ, De Hoog CL, Mann M (2003) Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci U S A 100: 5813-5818.
42. Li N, Mak A, Richards DP, Naber C, Keller BO, et al. (2003) Monocyte lipid rafts contain proteins implicated in vesicular trafficking and phagosome formation. Proteomics 3: 536-548.
43. Li N, Shaw AR, Zhang N, Mak A, Li L (2004) Lipid raft proteomics: analysis of in-solution digest of sodium dodecyl sulfate-solubilized lipid raft proteins by liquid chromatography-matrix-assisted laser desorption/ionization tandem mass spectrometry. Proteomics 4: 3156-3166.
44. von Haller PD, Donohoe S, Goodlett DR, Aebersold R, Watts JD (2001) Mass spectrometric characterization of proteins extracted from Jurkat T cell detergent-resistant membrane domains. Proteomics 1: 1010-1021.
45. Scheiffele P, Rietveld A, Wilk T, Simons K (1999) Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem 274: 2038-2044.
46. Nayak DP, Hui EK, Barman S (2004) Assembly and budding of influenza virus. Virus Res 106: 147-165.
47. O'Neill E, Donis RO (2009) Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. Curr Top Microbiol Immunol 333: 83-108.
48. Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, et al. (2009) Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A 106: 18137-18142.